



An unusual skin rash in a person with type 1 diabetes 
 
J.L.Kew1 
ORCID identifier: 0000-0003-4355-7506 
S.C. Bain1,2 
0000-0001-8519-4964 
1Swansea Bay University Health Board, Singleton Hospital, Swansea and 2Swansea University Medical School, 
Swansea UK 
A 73 year old man with long-standing type 1 diabetes attends for annual review. He has a previous medical history of 
Graves’ disease treated with radio-iodine and is now taking thyroxine. He complains of a non-itchy rash on the anterior 
aspect of his lower legs that has developed over the past six months. Examination reveals bilateral non-pitting dermal 




1. What is the diagnosis? 
2. What is the pathophysiology of this condition? 
3. What treatment is recommended for this condition?  
 
Answers 
1. The diagnosis is pretibial myxoedema. This is identifiable by the characteristic pretibial site, faintly pigmented 
thickening of the skin, scattered papules/nodules and the bilateral non-pitting dermal oedema (1-2). Pretibial 
myxoedema can occasionally involve the ankles, knees or feet and typically appears insidiously over three to twelve 
months. It is most often asymptomatic or itchy but is sometimes painful (1-2).  Pretibial myxoedema is almost 
exclusively seen in patients with Graves’ disease and the related ophthalmopathy. It is infrequently seen in patients 
with Hashimoto’s thyroiditis and is extremely rarely (case reports) seen in patients with no prior history of thyroid 
disease (3).  
2. Pretibial myxoedema is the result of an inflammatory process. Cytokine-induced activation of fibroblasts leads to the 
secretion of acidic glycosaminoglycans (GAGs) into the dermis (4). These GAGs are hydrophilic, compress dermal 
lymphatics and degrade dermal collagen fibres resulting in the clinical features described above (4). Almost all 
individuals with pretibial myxoedema have high levels of thyroid stimulating hormone receptor antibodies, and it is 
presumed these activate TSH receptors on fibroblasts, the initiating factor in this cellular process (5). 
  
3. If mild, no treatment is needed. For moderate and severe cases, first line therapy is topical corticosteroids (mid to 
high potency) with occlusion (e.g. wrapping legs in ‘cling film’) (6).  Second line treatment is systemic oral steroids or 
steroid injection into the lesions (7). In more refractory cases, studies using immunomodulating therapies are promising; 
these include pentoxifylline, rituximab, plasmapheresis and intravenous immunoglobulins. 
 
Learning Points  
Pretibial myxoedema is an uncommon immune-mediated condition most commonly associated with Graves’ disease 
with ophthalmopathy. 
If symptomatic, treatment involves topical or systemic corticosteroids and if refractory, immunomodulating therapies 
can be tried.  
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